J Clin Oncol 2019 Dec 27
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Related Questions
The patient is 94 years old and not a candidate for intensive chemotherapy. Neutrophilia is controlled with low-dose hydroxyurea. She harbors a CSF3R ...
New answer by at University of Chicago (October 21, 2025)
Assuming the CSF3R mutation that is seen is the T618I mutation, you can consider ruxolitinib. Dao et al., PMID 31880950, reported on a prospective trial of ruxolitinib in 44 p...